Interleukin 13 and its role in gut defence and inflammation

Gut

Volumn 61, Issue 12, 2012, Pages 1765-1773

  Mannon, Peter ^a   Reinisch, Walter ^b  

^a University of Alabama at Birmingham   (United States)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 308; AIR 645; AMG 317; ANRUKINZUMAB; CNTO 5825; DUPILUMAB; IMA 026; INTERLEUKIN 13; INTERLEUKIN 13 ANTIBODY; INTERLEUKIN 13 RECEPTOR ALPHA1; INTERLEUKIN 13 RECEPTOR ALPHA2; INTERLEUKIN 4 ANTIBODY; INTERLEUKIN 4 RECEPTOR ALPHA; LEBRIKIZUMAB; PITRAKINRA; PLACEBO; QAX 576; QBX 258; SAR 156597; TRALOKINUMAB; UNCLASSIFIED DRUG; VAK 694;

ALLERGIC ASTHMA; ALLERGIC RHINITIS; ANUS FISTULA; ASTHMA; BINDING KINETICS; CLINICAL TRIAL (TOPIC); CYTOKINE PRODUCTION; CYTOKINE RELEASE; DIGESTIVE SYSTEM INFLAMMATION; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG RESEARCH; EOSINOPHILIC ASTHMA; EOSINOPHILIC ESOPHAGITIS; FIBROSING ALVEOLITIS; HELMINTHIASIS; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; INTESTINAL FIBROSIS; INTESTINE MOTILITY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; RECEPTOR BINDING; RECEPTOR BLOCKING; REVIEW; SIGNAL TRANSDUCTION; ULCERATIVE COLITIS;

ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; COLITIS, ULCERATIVE; EOSINOPHILIC ESOPHAGITIS; FIBROSIS; GASTROINTESTINAL TRACT; HUMANS; IMMUNITY, INNATE; INFLAMMATION; INTERLEUKIN-13; INTESTINAL MUCOSA; INTESTINES; RECEPTORS, INTERLEUKIN-13;

EID: 84868688331     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2012-303461     Document Type: Review

References (112)

1. McKenzie AN, Li X, Largaespada DA, et al. Structural comparison and chromosomal localization of the human and mouse IL-13 genes. J Immunol 1993;150:5436-44. (Pubitemid 23180657)
2. Rogan DF, Cousins DJ, Santangelo S, et al. Analysis of intergenic transcription in the human IL-4/IL-13 gene cluster. Proc Natl Acad Sci USA 2004;101:2446-51.
3. Syn WK, Witek RP, Curbishley SM, et al. Role for hedgehog pathway in regulating growth and function of invariant NKT cells. Eur J Immunol 2009;39:1879-92.
4. Fuss IJ, Heller F, Boirivant M, et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest 2004;113:1490-7. (Pubitemid 39071705)
5. Smithgall MD, Comeau MR, Yoon BR, et al. IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int Immunol 2008;20:1019-30.
6. Toru H, Pawankar R, Ra C, et al. Human mast cells produce IL-13 by high-affinity IgE receptor cross-linking: enhanced IL-13 production by IL-4-primed human mast cells. J Allergy Clin Immunol 1998;102:491-502.
7. Woerly G, Lacy P, Younes AB, et al. Human eosinophils express and release IL-13 following CD28-dependent activation. J Leukoc Biol 2002;72:769-79. (Pubitemid 36277849)
8. Koyasu S, Moro K. Type 2 innate immune responses and the natural helper cell. Immunology 2011;132:475-81.
9. Zhao A, Urban JF Jr, Sun R, et al. Critical role of IL-25 in nematode infection-induced alterations in intestinal function. J Immunol 2010;185:6921-9.
10. Pastorelli L, Garg RR, Hoang SB, et al. Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc Natl Acad Sci USA 2010;107:8017-22.
11. Beltran CJ, Nunez LE, Diaz-Jimenez D, et al. Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease. Inflamm Bowel Dis 2010;16:1097-107.
12. Tanaka J, Saga K, Kido M, et al. Proinflammatory Th2 cytokines induce production of thymic stromal lymphopoietin in human colonic epithelial cells. Dig Dis Sci 2010;55:1896-904.
13. Fort MM, Cheung J, Yen D, et al. IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity 2001;15:985-95. (Pubitemid 34075378)
14. Yasuda K, Muto T, Kawagoe T, et al. Contribution of IL-33-activated type II innate lymphoid cells to pulmonary eosinophilia in intestinal nematode-infected mice. Proc Natl Acad Sci USA 2012;109:3451-6.
15. Mjosberg JM, Trifari S, Crellin NK, et al. Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161. Nat Immunol 2011;12:1055-62.
16. Iwashita J, Sato Y, Sugaya H, et al. mRNA of MUC2 is stimulated by IL-4, IL-13 or TNF-alpha through a mitogen-activated protein kinase pathway in human colon cancer cells. Immunol Cell Biol 2003;81:275-82. (Pubitemid 36904334)
17. Wright K, Kolios G, Westwick J, et al. Cytokine-induced apoptosis in epithelial HT-29 cells is independent of nitric oxide formation. Evidence for an interleukin-13-driven phosphatidylinositol 3-kinase-dependent survival mechanism. J Biol Chem 1999;274:17193-201.
18. Atherton HC, Jones G, Danahay H. IL-13-induced changes in the goblet cell density of human bronchial epithelial cell cultures: MAP kinase and phosphatidylinositol 3-kinase regulation. Am J Physiol Lung Cell Mol Physiol 2003;285:L730-9. (Pubitemid 37022875)
19. Hecker M, Zaslona Z, Kwapiszewska G, et al. Dysregulation of the IL-13 receptor system: a novel pathomechanism in pulmonary arterial hypertension. Am J Respir Crit Care Med 2010;182:805-18.
20. Andrews AL, Holloway JW, Puddicombe SM, et al. Kinetic analysis of the interleukin-13 receptor complex. J Biol Chem 2002;277:46073-8. (Pubitemid 35417594)
21. Kasaian MT, Raible D, Marquette K, et al. IL-13 antibodies influence IL-13 clearance in humans by modulating scavenger activity of IL-13Ralpha2. J Immunol 2011;187:561-9.
22. Yasunaga S, Yuyama N, Arima K, et al. The negative-feedback regulation of the IL-13 signal by the IL-13 receptor alpha2 chain in bronchial epithelial cells. Cytokine 2003;24:293-303. (Pubitemid 37373665)
23. Andrews AL, Nasir T, Bucchieri F, et al. IL-13 receptor alpha 2: a regulator of IL-13 and IL-4 signal transduction in primary human fibroblasts. J Allergy Clin Immunol 2006;118:858-65. (Pubitemid 44515110)
24. Rahaman SO, Sharma P, Harbor PC, et al. IL-13R(alpha)2, a decoy receptor for IL-13 acts as an inhibitor of IL-4-dependent signal transduction in glioblastoma cells. Cancer Res 2002;62:1103-9. (Pubitemid 34160294)
25. Barderas R, Bartolome RA, Fernandez-Acenero MJ, et al. High expression of IL-13 receptor alpha2 in colorectal cancer is associated with invasion, liver metastasis, and poor prognosis. Cancer Res 2012;72:2780-90.
26. Fichtner-Feigl S, Strober W, Kawakami K, et al. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med 2006;12:99-106. (Pubitemid 43050083)
27. Rahaman SO, Vogelbaum MA, Haque SJ. Aberrant Stat3 signaling by interleukin-4 in malignant glioma cells: involvement of IL-13Ralpha2. Cancer Res 2005;65:2956-63. (Pubitemid 40490101)
28. Chen W, Tabata Y, Gibson AM, et al. Matrix metalloproteinase 8 contributes to solubilization of IL-13 receptor alpha2 in vivo. J Allergy Clin Immunol 2008;122:625-32.
29. Matsumura M, Inoue H, Matsumoto T, et al. Endogenous metalloprotease solubilizes IL-13 receptor alpha2 in airway epithelial cells. Biochem Biophys Res Commun 2007;360:464-9. (Pubitemid 47030366)
30. Tabata Y, Chen W, Warrier MR, et al. Allergy-driven alternative splicing of IL-13 receptor alpha2 yields distinct membrane and soluble forms. J Immunol 2006;177:7905-12. (Pubitemid 44846306)
31. Kaser A, Molnar C, Tilg H. Differential regulation of interleukin 4 and interleukin 13 production by interferon alpha. Cytokine 1998;10:75-81. (Pubitemid 28077705)
32. Daines MO, Hershey GK. A novel mechanism by which interferon-gamma can regulate interleukin (IL)-13 responses. Evidence for intracellular stores of IL-13 receptor alpha -2 and their rapid mobilization by interferon-gamma. J Biol Chem 2002;277:10387-93. (Pubitemid 34968158)
33. Konstantinidis AK, Puddicombe SM, Mochizuki A, et al. Cellular localization of interleukin 13 receptor alpha2 in human primary bronchial epithelial cells and fibroblasts. J Investig Allergol Clin Immunol 2008;18:174-80. (Pubitemid 351872283)
34. Dickensheets HL, Venkataraman C, Schindler U, et al. Interferons inhibit activation of STAT6 by interleukin 4 in human monocytes by inducing SOCS-1 gene expression. Proc Natl Acad Sci USA 1999;96:10800-5. (Pubitemid 29442224)
35. Wu D, Ahrens R, Osterfeld H, et al. Interleukin-13 (IL-13)/IL-13 receptor alpha1 (IL-13Ralpha1) signaling regulates intestinal epithelial cystic fibrosis transmembrane conductance regulator channel-dependent Cl- secretion. J Biol Chem 2011;286:13357-69.
36. Hering NA, Fromm M, Schulzke JD. Determinants of colonic barrier function in inflammatory bowel disease and potential therapeutics. J Physiol 2012;590(Pt 5):1035-44.
37. Bancroft AJ, McKenzie AN, Grencis RK. A critical role for IL-13 in resistance to intestinal nematode infection. J Immunol 1998;160:3453-61. (Pubitemid 28164739)
38. Urban JF Jr, Noben-Trauth N, Donaldson DD, et al. IL-13, IL-4Ralpha, and Stat6 are required for the expulsion of the gastrointestinal nematode parasite Nippostrongylus brasiliensis. Immunity 1998;8(2):255-64. (Pubitemid 28123752)
39. Else KJ, Grencis RK. Antibody-independent effector mechanisms in resistance to the intestinal nematode parasite Trichuris muris. Infect Immun 1996;64:2950-4. (Pubitemid 26256131)
40. Gaze S, McSorley HJ, Daveson J, et al. Characterising the mucosal and systemic immune responses to experimental human hookworm infection. PLoS Pathog 2012;8:e1002520.
41. Newcomb DC, Boswell MG, Huckabee MM, et al. IL-13 regulates Th17 secretion of IL-17A in an IL-10-dependent manner. J Immunol 2012;188:1027-35.
42. Newcomb DC, Zhou W, Moore ML, et al. A functional IL-13 receptor is expressed on polarized murine CD4+ Th17 cells and IL-13 signaling attenuates Th17 cytokine production. J Immunol 2009;182:5317-21.
43. Newcomb DC, Boswell MG, Zhou W, et al. Human TH17 cells express a functional IL-13 receptor and IL-13 attenuates IL-17A production. J Allergy Clin Immunol 2011;127:1006-13 e1-4.
44. Wilson MS, Ramalingam TR, Rivollier A, et al. Colitis and intestinal inflammation in IL10-/- mice results from IL-13Ralpha2-mediated attenuation of IL-13 activity. Gastroenterology 2011;140:254-64.
45. Farmer DG, Ke B, Shen XD, et al. Interleukin-13 protects mouse intestine from ischemia and reperfusion injury through regulation of innate and adaptive immunity. Transplantation 2011;91:737-43.
46. Kucharzik T, Lugering N, Weigelt H, et al. Immunoregulatory properties of IL-13 in patients with inflammatory bowel disease; comparison with IL-4 and IL-10. Clin Exp Immunol 1996;104:483-90. (Pubitemid 26171566)
47. Kolios G, Wright KL, Linehan JD, et al. Interleukin-13 inhibits nitric oxide production in human colonic mucosa. Hepatogastroenterology 2000;47:714-17. (Pubitemid 30417279)
48. Morimoto M, Morimoto M, Zhao A, et al. Functional importance of regional differences in localized gene expression of receptors for IL-13 in murine gut. J Immunol 2006;176:491-5. (Pubitemid 43023295)
49. Mandal D, Levine AD. Elevated IL-13Ralpha2 in intestinal epithelial cells from ulcerative colitis or colorectal cancer initiates MAPK pathway. Inflamm Bowel Dis 2010;16:753-64.
50. Heller F, Florian P, Bojarski C, et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 2005;129:550-64. (Pubitemid 41096643)
51. Scharl M, Frei S, Pesch T, et al. Interleukin-13 and transforming growth factor beta synergise in the pathogenesis of human intestinal fistulae. Gut Published Online First: 27 Jan 2012. doi:10.1136/gutjnl-2011-300498
52. McDermott JR, Humphreys NE, Forman SP, et al. Intraepithelial NK cell-derived IL-13 induces intestinal pathology associated with nematode infection. J Immunol 2005;175:3207-13. (Pubitemid 41170541)
53. Rothenberg ME, Wen T, Shik D, et al. IL-13 receptor alpha1 differentially regulates aeroallergen-induced lung responses. J Immunol 2011;187:4873-80.
54. Munitz A, Brandt EB, Mingler M, et al. Distinct roles for IL-13 and IL-4 via IL-13 receptor alpha1 and the type II IL-4 receptor in asthma pathogenesis. Proc Natl Acad Sci USA 2008;105:7240-5. (Pubitemid 351754462)
55. Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011;365:1088-98.
56. Gauvreau GM, Boulet LP, Cockcroft DW, et al. Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma. Am J Respir Crit Care Med 2011;183:1007-14.
57. Fuschiotti P, Medsger TA Jr, Morel PA. Effector CD8+ T cells in systemic sclerosis patients produce abnormally high levels of interleukin-13 associated with increased skin fibrosis. Arthritis Rheum 2009;60:1119-28.
58. Oh MH, Oh SY, Yu J, et al. IL-13 induces skin fibrosis in atopic dermatitis by thymic stromal lymphopoietin. J Immunol 2011;186:7232-42.
59. Medsger TA Jr, Ivanco DE, Kardava L, et al. GATA-3 up-regulation in CD8+ T cells as a biomarker of immune dysfunction in systemic sclerosis, resulting in excessive interleukin-13 production. Arthritis Rheum 2011;63:1738-47.
60. Boirivant M, Fuss IJ, Chu A, et al. Oxazolone colitis: a murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4. J Exp Med 1998;188:1929-39. (Pubitemid 28536780)
61. Heller F, Fuss IJ, Nieuwenhuis EE, et al. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity 2002;17:629-38. (Pubitemid 35351508)
62. Scanlon ST, Thomas SY, Ferreira CM, et al. Airborne lipid antigens mobilize resident intravascular NKT cells to induce allergic airway inflammation. J Exp Med 2011;208:2113-24.
63. Camelo A, Barlow JL, Drynan LF, et al. Blocking IL-25 signalling protects against gut inflammation in a type-2 model of colitis by suppressing nuocyte and NKT derived IL-13. J Gastroenterol Published Online First: 27 Apr 2012. doi: 10.1007/s00535-012-0591-2
64. Rosen MJ, Frey MR, Washington MK, et al. STAT6 activation in ulcerative colitis: a new target for prevention of IL-13-induced colon epithelial cell dysfunction. Inflamm Bowel Dis 2011;17:2224-34.
65. Kawashima R, Kawamura YI, Oshio T, et al. Interleukin-13 damages intestinal mucosa via TWEAK and Fn14 in mice-a pathway associated with ulcerative colitis. Gastroenterology 2011;141:2119-29 e8.
66. Wood N, Whitters MJ, Jacobson BA, et al. Enhanced interleukin (IL)-13 responses in mice lacking IL-13 receptor alpha 2. J Exp Med 2003;197:703-9. (Pubitemid 36350865)
67. Vladich FD, Brazille SM, Stern D, et al. IL-13 R130Q, a common variant associated with allergy and asthma, enhances effector mechanisms essential for human allergic inflammation. J Clin Invest 2005;115:747-54. (Pubitemid 40322251)
68. DeMeo DL, Lange C, Silverman EK, et al. Univariate and multivariate family-based association analysis of the IL-13 ARG130GLN polymorphism in the Childhood Asthma Management Program. Genet Epidemiol 2002;23:335-48. (Pubitemid 35416672)
69. Granel B, Chevillard C, Allanore Y, et al. Evaluation of interleukin 13 polymorphisms in systemic sclerosis. Immunogenetics 2006;58:693-9. (Pubitemid 44100416)
70. Heinzmann A, Mao XQ, Akaiwa M, et al. Genetic variants of IL-13 signalling and human asthma and atopy. Hum Mol Genet 2000;9:549-59. (Pubitemid 30154013)
71. Howard TD, Whittaker PA, Zaiman AL, et al. Identification and association of polymorphisms in the interleukin-13 gene with asthma and atopy in a Dutch population. Am J Respir Cell Mol Biol 2001;25:377-84. (Pubitemid 32918921)
72. Waterman M, Karban A, Nesher S, et al. (The significance of IL-13 gene +2044G/A mutation in patients with inflammatory bowel disease). Harefuah 2006;145:789-92, 864.
73. Arijs I, Li K, Toedter G, et al. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut 2009;58:1612-19.
74. Bakshi S, Zhang X, Godoy-Tundidor S, et al. Transcriptome analyses in normal prostate epithelial cells exposed to low-dose cadmium: oncogenic and immunomodulations involving the action of tumor necrosis factor. Environ Health Perspect 2008;116:769-76. (Pubitemid 351943933)
75. Mannon PJ, Hornung RL, Yang Z, et al. Suppression of inflammation in ulcerative colitis by interferon-beta-1a is accompanied by inhibition of IL-13 production. Gut 2011;60:449-55.
76. Gonsalves N, Yang GY, Doerfler B, et al. Elimination diet effectively treats eosinophilic esophagitis in adults; food reintroduction identifies causative factors. Gastroenterology 2012;142:1451-9 e1.
77. Mishra A, Rothenberg ME. Intratracheal IL-13 induces eosinophilic esophagitis by an IL-5, eotaxin-1, and STAT6-dependent mechanism. Gastroenterology 2003;125:1419-27. (Pubitemid 37409762)
78. Akei HS, Mishra A, Blanchard C, et al. Epicutaneous antigen exposure primes for experimental eosinophilic esophagitis in mice. Gastroenterology 2005;129:985-94. (Pubitemid 41242689)
79. Zuo L, Fulkerson PC, Finkelman FD, et al. IL-13 induces esophageal remodeling and gene expression by an eosinophil-independent, IL-13R alpha 2-inhibited pathway. J Immunol 2010;185:660-9.
80. Neilsen CV, Bryce PJ. Interleukin-13 directly promotes oesophagus production of CCL11 and CCL24 and the migration of eosinophils. Clin Exp Allergy 2010;40:427-34.
81. Blanchard C, Stucke EM, Rodriguez-Jimenez B, et al. A striking local esophageal cytokine expression profile in eosinophilic esophagitis. J Allergy Clin Immunol 2011;127:208-17, 17 e1-7.
82. Frischmeyer-Guerrerio PA, Guerrerio AL, Chichester KL, et al. Dendritic cell and T cell responses in children with food allergy. Clin Exp Allergy 2011;41:61-71.
83. Sherrill JD, Rothenberg ME. Genetic dissection of eosinophilic esophagitis provides insight into disease pathogenesis and treatment strategies. J Allergy Clin Immunol 2011;128:23-32; quiz 3-4.
84. Blanchard C, Stucke EM, Burwinkel K, et al. Coordinate interaction between IL-13 and epithelial differentiation cluster genes in eosinophilic esophagitis. J Immunol 2010;184:4033-41.
85. Matsushita M, Yamamoto T, Nishioka K. Upregulation of interleukin-13 and its receptor in a murine model of bleomycin-induced scleroderma. Int Arch Allergy Immunol 2004;135:348-56. (Pubitemid 40082202)
86. Riccieri V, Rinaldi T, Spadaro A, et al. Interleukin-13 in systemic sclerosis: relationship to nailfold capillaroscopy abnormalities. Clin Rheumatol 2003;22:102-6. (Pubitemid 36748857)
87. Chiaramonte MG, Donaldson DD, Cheever AW, et al. An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. J Clin Invest 1999;104:777-85. (Pubitemid 29536363)
88. Wallace WA, Ramage EA, Lamb D, et al. A type 2 (Th2-like) pattern of immune response predominates in the pulmonary interstitium of patients with cryptogenic fibrosing alveolitis (CFA). Clin Exp Immunol 1995;101:436-41.
89. Zhu Z, Homer RJ, Wang Z, et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest 1999;103:779-88. (Pubitemid 29152623)
90. Wilson MS, Wynn TA. Pulmonary fibrosis: pathogenesis, etiology and regulation. Mucosal Immunol 2009;2:103-21.
91. Lee CG, Homer RJ, Zhu Z, et al. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). J Exp Med 2001;194:809-21. (Pubitemid 32983016)
92. Edwards FC, Truelove SC. The course and prognosis of ulcerative colitis. III. Complications. Gut 1964;5:1-22.
93. Gumaste V, Sachar DB, Greenstein AJ. Benign and malignant colorectal strictures in ulcerative colitis. Gut 1992;33:938-41.
94. Maul J, Zeitz M. Ulcerative colitis: immune function, tissue fibrosis and current therapeutic considerations. Langenbecks Arch Surg 2012;397:1-10.
95. Akiho H, Deng Y, Blennerhassett P, et al. Mechanisms underlying the maintenance of muscle hypercontractility in a model of postinfective gut dysfunction. Gastroenterology 2005;129:131-41. (Pubitemid 41002050)
96. Mizutani T, Akiho H, Khan WI, et al. Persistent gut motor dysfunction in a murine model of T-cell-induced enteropathy. Neurogastroenterol Motil 2010;22:196-203, e65.
97. Kindt S, Van Oudenhove L, Broekaert D, et al. Immune dysfunction in patients with functional gastrointestinal disorders. Neurogastroenterol Motil 2009;21:389-98.
98. May RD, Monk PD, Cohen ES, et al. Preclinical development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe uncontrolled asthma. Br J Pharmacol 2012;166:177-93.
99. Kasaian MT, Tan XY, Jin M, et al. Interleukin-13 neutralization by two distinct receptor blocking mechanisms reduces immunoglobulin E responses and lung inflammation in cynomolgus monkeys. J Pharmacol Exp Ther 2008;325:882-92. (Pubitemid 351724334)
100. Nakashima H, Husain SR, Puri RK. IL-13 receptor-directed cancer vaccines and immunotherapy. Immunotherapy 2012;4:443-51.
101. Mannon P, Miner PB, Lukas M, et al. Secondary efficacy analysis from a phase IIa multicenter study with interferon-â-1a for induction of clinical response in active moderate to severe ulcerative colitis. Am J Gastroenterol 2010;105:S446.
102. Piper E, Brightling C, Niven R, et al. Phase 2 randomized, double-blind, placebo-controlled study of tralokinumab, an anti-IL-13 monoclonal antibody, in moderate to severe asthma. Eur Respir J Published Online First: 27 Jun 2012. doi:10.1183/09031936.00223411 abstract 3425.
103. Nicholson GC, Kariyawasam HH, Tan AJ, et al. The effects of an anti-IL-13 mAb on cytokine levels and nasal symptoms following nasal allergen challenge. J Allergy Clin Immunol 2011;128:800-7, e9.
104. Ying H, Miller R, Bose S, et al. ABT-308, A highly potent anti-IL-13 therapeutic antibody for the treatment of human asthma. Am J Respir Crit Care Med 2010;181:A6644.
105. Corren J, Busse W, Meltzer EO, et al. A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. Am J Respir Crit Care Med 2010;181:788-96.
106. Kakkar T, Sung C, Gibiansky L, et al. Population PK and IgE pharmacodynamic analysis of a fully human monoclonal antibody against IL4 receptor. Pharm Res 2011;28:2530-42.
107. Wenzel S, Wilbraham D, Fuller R, et al. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 2007;370:1422-31. (Pubitemid 47576168)
108. Otulana BA, Wenzel SE, Ind PW, et al. A phase 2b study of inhaled pitrakinra, an IL-4/IL-13 antagonist, successfully identified responder subpopulations of patients with uncontrolled asthma. Am J Respir Crit Care Med 2011;183:A6179.
109. Wenzel SE, Ind PW, Otulana BA, et al. Inhaled pitrakinra, an IL-4/IL-13 antagonist, reduced exacerbations in patients with eosinophilic asthma. Eur Resp Soc Annual Congress 2010:abstract 3980.
110. Slager RE, Hawkins GA, Ampleford EJ, et al. IL-4 receptor alpha polymorphisms are predictors of a pharmacogenetic response to a novel IL-4/IL-13 antagonist. J Allergy Clin Immunol 2010;126:875-8.
111. Hodges M, Castelloe E, Chen A, et al. A phase 1 multiple dose safety and pharmacokinetics study of AIR645, an inhaled IL-4rα 2-MOE GAPMER oligonucleotide. Eur Resp Soc Annual Congress 2009:abstract 1800.
112. Hodges MR, Castelloe E, Chen A, et al. Randomized, double-blind, placebo controlled first in human study of inhaled AIR645, an IL-4R{alpha} oligonucleotide, in healthy volunteers. Am J Respir Crit Care Med 2009;179:A3640.